UK markets open in 2 hours 8 minutes
NIKKEI 225
38,848.24 -74.76 (-0.19%) HANG SENG
18,441.59 +38.59 (+0.21%) CRUDE OIL
73.58 -0.64 (-0.86%) GOLD FUTURES
2,369.20 -0.10 (-0.00%) DOW
38,571.03 -115.27 (-0.30%) Bitcoin GBP
53,981.31 +541.55 (+1.01%)
Biogen Inc. (4BIIB.TI)
TLO - TLO Delayed price. Currency in EUR
Add to watchlist
At close: 01:24PM CEST
| Previous close | 207.00 |
| Open | 202.40 |
| Bid | 210.40 x N/A |
| Ask | 216.40 x N/A |
| Day's range | 202.40 - 202.40 |
| 52-week range | 178.90 - 291.20 |
| Volume | |
| Avg. volume | 3 |
| Market cap | N/A |
| Beta (5Y monthly) | -0.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Benzinga
Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
On Thursday, the European Commission granted marketing authorization under exceptional circumstances and maintained orphan designation for Biogen Inc’s (NASDAQ:BIIB) Qalsody (tofersen) for amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 gene (SOD1-ALS). Qalsody is the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND). SOD1-ALS is an ultra-rare genetic form of ALS estimated to affe
- Zacks
Repligen (RGEN) Down 10.9% Since Last Earnings Report: Can It Rebound?
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks
Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody
Biogen's (BIIB) Qalsody is the first therapy approved to treat a rare genetic form of ALS in Europe
© 2024 Yahoo. All rights reserved.